Genmab to expand Arzerra
New positive data from a phase III study with the Genmab drug, Arzerra, against leukaemia will pave the way for new treatment options for the drug, which is already generating millions in royalties for the Danish company.
by Stefan Singh Kailay
Danish Genmab and its British partner GlaxoSmithKline has announced positive top-line results from a phase III study with the Drug Arzerra.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
